3SBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 HKD | +0.50% |
|
+9.35% | -19.15% |
| Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
| Sales 2023 | 7.82B 1.08B 8.44B | Sales 2024 * | 8.65B 1.19B 9.34B | Capitalization | 13.34B 1.84B 14.41B |
|---|---|---|---|---|---|
| Net income 2023 | 1.55B 214M 1.67B | Net income 2024 * | 1.93B 267M 2.09B | EV / Sales 2023 | 2.37 x |
| Net Debt 2023 | 2.15B 296M 2.32B | Net Debt 2024 * | 866M 119M 935M | EV / Sales 2024 * | 1.64 x |
| P/E ratio 2023 |
11
x | P/E ratio 2024 * |
7.36
x | Employees | 5,411 |
| Yield 2023 * |
2.87% | Yield 2024 * |
3.89% | Free-Float | 73.96% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.50% | ||
| 1 week | +9.35% | ||
| Current month | +1.67% | ||
| 1 month | +2.70% | ||
| 3 months | +2.88% | ||
| 6 months | -3.65% | ||
| Current year | -19.15% |
1 week
5.51
6.20
1 month
5.506.35
Current year
4.917.52
1 year
4.918.10
3 years
4.7212.30
5 years
4.7215.22
10 years
4.7223.25
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Xiang He
DFI | Director of Finance/CFO | - | 23-07-02 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bin Huang
BRD | Director/Board Member | 63 | 92-12-31 |
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 4 M€ | -27.92% | ||
| 0.63% | 2 M€ | -18.13% | - | |
| 0.23% | 2 M€ | -14.14% | ||
| 0.19% | 4 M€ | -11.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.08 | +0.50% | 10 085 120 |
| 24-04-25 | 6.05 | +3.77% | 14,719,650 |
| 24-04-24 | 5.83 | +1.75% | 5,112,500 |
| 24-04-23 | 5.73 | +2.50% | 8,753,000 |
| 24-04-22 | 5.59 | +0.54% | 6,712,500 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Companyâs main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Companyâs subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5.599
CNY
Average target price
6.887
CNY
Spread / Average Target
+23.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.15% | 1.84B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.39% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.42% | 8.75B |
- Stock Market
- Equities
- 1530 Stock
